Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 12/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869493 | 0.83 | EIF2AK3 (0.47) | EIF2AK3MAPK1RIPK1PIK3CDCYP3A4 | |
| SCHEMBL14655779 | 0.78 | EIF2AK3 (0.51) | EIF2AK3CYP11B1CYP11B2RIPK1EIF2AK1 | |
| SCHEMBL869246 | 0.75 | EIF2AK3 (0.48) | EIF2AK3CYP11B1CYP11B2RIPK1EIF2AK1 | |
| SCHEMBL6926794 | 0.72 | EIF2AK3 (0.60) | EIF2AK3RIPK1EIF2AK1 | |
| SCHEMBL868753 | 0.71 | EIF2AK3 (0.37) | EIF2AK3MAPK1RIPK1CYP3A4EIF2AK1 | |
| SCHEMBL14655630 | 0.64 | EIF2AK3 (0.61) | EIF2AK3MAPK1CYP11B1CYP11B2PIK3CD | |
| SCHEMBL14655668 | 0.63 | EIF2AK3 (0.60) | EIF2AK3MAPK1CYP11B1CYP11B2RIPK1 | |
| SCHEMBL868362 | 0.61 | EIF2AK3 (0.63) | EIF2AK3RIPK1EIF2AK1 | |
| SCHEMBL14576841 | 0.61 | EIF2AK3 (0.67) | EIF2AK3RIPK1EIF2AK1 | |
| SCHEMBL869492 | 0.60 | EIF2AK3 (0.56) | EIF2AK3MAPK1RIPK1EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885MAPK1 5/4885CYP11B1 341/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885MAPK1 5/4885CYP11B1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.